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Introduction: Vasculitis has been associated with malignancies, more commonly hematological rather than solid
malignancies. Due to the rarity of these conditions and the lack of a temporal association, the relationship between
vasculitis and malignancy remains unclear. Paraneoplastic vasculitis as a phenomenon of lung cancer has been
described in the literature. To the best of our knowledge, this is the first case report of leukocytoclastic vasculitis
being an initial presentation of malignant pleural mesothelioma.
Case presentation: We report the case of an 84-year old Greek man who presented to our facility with an
erythematous, pruritic and purpuric rash affecting his limbs. This was biopsy-proven to be leukocytoclastic vasculitis
and treated conservatively with topical corticosteroids as well as oral prednisolone, with good results. Six months
later, he was diagnosed as having malignant pleural mesothelioma. As he remained asymptomatic from his
malignancy, no systemic chemotherapy was instituted. He had a recurrence of biopsy-proven leukocytoclastic
vasculitis two months after he was diagnosed as having mesothelioma, which again settled with conservative
measures.
Conclusions: It is important to remain vigilant with regard to the association between leukocytoclastic vasculitis
and malignancies. A diagnosis of vasculitis requires a search for malignancies as well as other possible etiologies.
This is particularly of relevance when the vasculitis becomes chronic, recurrent or treatment is no longer effective.
Should our patient have experienced refractory vasculitis, we would have instituted systemic chemotherapy to
treat the underlying malignancy.
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Leukocytoclastic vasculitis (LCV) is a small-vessel inflam-
matory disease mediated by deposition of immune com-
plexes. It usually occurs in the setting of an underlying
process, such as medication exposure, infection, malig-
nancy, connective tissue disease or as a manifestation of a
primary systemic vasculitis [1]. Vasculitis has been asso-
ciated more commonly with hematological rather than
solid malignancies [2]. The mechanism by which malig-
nancies cause vasculitis remains unclear. This report illus-
trates a rare case of paraneoplastic LCV as an initial
presentation of malignant pleural mesothelioma (MPM).* Correspondence: Shane.white@austin.org.au
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An 84-year-old previously well Greek man presented to
our facility with a one-month history of an erythema-
tous, scaly and pruritic rash that progressed from his left
medial malleolus (Figure 1) to involve his lower legs and
hands (Figure 2). There were associated superficial ero-
sions and hemorrhagic bullae of the hands, which were
painful and interfering with his daily function. His only
significant medical history included hypertension and al-
lergic rhinitis for which he was not on medication.
There was no history of smoking, asbestos exposure or
recent infections.
Investigations indicated mild lymphopenia of 0.7 ×
109 cells/L (normal range: 1.0×109 cells/L to 4.0 ×
109 cells/L), elevated erythrocyte sedimentation rate
(ESR) of 85mm/hour (normal range: 5 to 12mm/hour)td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Multiple erythematous, papular and non-blanching
rash on lower legs.
Figure 3 Skin punch biopsy showing features of
leukocytoclastic vasculitis with peri-vascular fibrin, neutrophils
and leukocytoclasia (nuclear dust), which is indicated with an
arrow in the picture (hematoxylin and eosin stain; original
magnification×400).
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(normal range: <40U). Serum and urine protein electro-
phoresis, and a chest radiograph were unremarkable. A
punch biopsy of a rash on his hand confirmed IgA-
positive LCV involving vessels of the superficial and mid
dermis, with prominent peri-vascular fibrin, neutrophils
and leukocytoclasia (nuclear dust) (Figure 3). Immuno-
fluorescence studies demonstrated IgA and C3 depos-
ition in the walls of superficial vessels. He was treated
with oral prednisolone and topical corticosteroids with
resolution of the rash.
Six months later, he presented again with a right-sided
pleural effusion that contained atypical mesothelial
cells on drainage, raising the suspicion of MPM. A sub-
sequent video-assisted thoracoscopic surgery biopsy
confirmed biphasic MPM involving the parietal pleura.
Laboratory tests demonstrated thrombocytosis of 628 ×
109 cells/L (normal range: 150×109 cells/L to 400 ×Figure 2 Painful, palpable rash with hemorrhagic bullae
of hands.109 cells/L), elevated C-reactive protein of 293.3mg/L
(normal range: <8mg/L) and ESR of 58mm/hour (normal
range: 5 to 12mm/hour). A computed tomography scan
of the chest revealed right lower lobe collapse and diffi-
culty assessing for a mass lesion.
As he was otherwise asymptomatic, he declined sys-
temic chemotherapy. Two months after being diagnosed
as having MPM, he had a recurrence of biopsy-
confirmed LCV that again responded to oral prednisol-
one and topical corticosteroids. The MPM and LCV
have not required further treatment, such as chemother-
apy, as our patient remains asymptomatic.
Discussion
LCV is a small-vessel vasculitis featuring leukocytoclasia
of infiltrating granulocytes with fibrinoid necrosis of
the vascular wall and subsequent extravasation of ery-
throcytes [3]. The clinical hallmark of LCV includes
erythematous macules and urticarial papules, some-
times progressing to palpable purpura, which is usually
symmetric but can be diffuse as well [4]. In more than
70% of cases, LCV occurs in the setting of an underly-
ing process inclusive of medication exposure, infec-
tion, malignancy, connective tissue disease or as a
manifestation of a primary systemic vasculitis [1]. It is
classified as idiopathic vasculitis once other etiologies
have been excluded.
The occurrence of vasculitis with malignancy has been
postulated for many years. It has been estimated that
about 5% of patients with vasculitis may have an under-
lying related malignancy [5]. One retrospective review
[6] identified 69 patients with both cancer and malig-
nancy over an 18.5-year period. There were only 12
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culitis occurred within a 12-month period. The most
common vasculitis was cutaneous LCV, which occurred
in seven cases, with four of them being solid organ
malignancies. There was no observed predictable
response of vasculitis to treatment with glucocorticoids
and systemic chemotherapy. In comparison, a retro-
spective review conducted by Fain et al. [7] identified
60% of their patients (n=60) with vasculitis and malig-
nancy within a 12-month period. LCV was again the
most common vasculitis, accounting for 45% of all pa-
tient cases. Their review reported one case of mesotheli-
oma associated with vasculitis.
To the best of our knowledge, there have been no pre-
viously reported cases of paraneoplastic leukocytoclastic
vasculitis occurring with MPM. Our case illustrates that
vasculitis may not only be the presenting feature of
MPM but may even precede the diagnosis by a number
of months. Failure of LCV to respond to usually effective
therapies should prompt a search for underlying malig-
nancy. Treatment of paraneoplastic LCV should be
directed at the underlying malignancy or by using a
combination of corticosteroids and immunosuppresants,
especially in the case of hemorrhagic blisters or incipient
skin necrosis [3].
Conclusions
We report a case of paraneoplastic LCV as the initial
presentation of MPM. To the best of our knowledge, this
is the first case report of LCV presenting with MPM.
Corticosteroid treatment dramatically improved the
cutaneous LCV in our patient. Should the LCV have
been steroid refractory, systemic chemotherapy was con-
sidered the next option. However, this has not been
required to date and our patient remains well without
evidence of progression eight months after diagnosis.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
SF collected retrospective data from medical records and performed a
literature review for the condition. LN analyzed the histological samples and
identified illustration samples for the manuscript. SW and TJ reviewed the
manuscript and cleaned up the data. All authors reviewed and approved the
final manuscript.
Author details
1Austin Health, Department of Medical Oncology, 145 Studley Road,
Heidelberg, Victoria 3084, Australia. 2Department of Anatomical Pathology,
Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia.Received: 23 March 2012 Accepted: 26 June 2012
Published: 31 August 2012
References
1. Langford CA: Vasculitis. J Allergy Clin Immunol 2010, 125:S216–S225.
2. Greer JM, Longley S, Edwards NL, Elfenbein GJ, Panush RS: Vasculitis
associated with malignancy. Experience with 13 patients and literature
review. Medicine (Baltimore) 1988, 67:220–230.
3. Sunderkotter C, Bonsmann G, Sindrilaru A, Luger T: Management of
leukocytoclastic vasculitis. J Dermatolog Treat 2005, 16:193–206.
4. Swerlick R, Lawley T: Cutaneous vasculitis: its relationship to systemic
disease. Med Clin North Am 1989, 73:1221–1235.
5. Hayem G, Gomez M, Grossin M, Meyer O, Kahn M: Systemic vasculitis and
epithelioma: a report of three cases with a literature review. Rev Rhum
Eng Ed 1997, 64:816–824.
6. Hutson TE, Hoffman GS: Temporal concurrence of vasculitis and cancer: a
report of 12 cases. Arthritis Care Res 2000, 13:417–423.
7. Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, Pariès J, Stirnemann J,
Morin AS, Gatfosse M, Hanslik T, Belmatoug N, Blétry O, Cevallos R,
Delevaux I, Fisher E, Hayem G, Kaplan G, Le Hello C, Mouthon L,
Larroche C, Lemaire V, Piette AM, Piette JC, Ponge T, Puechal X, Rossert J,
Sarrot-Reynauld F, Sicard D, Ziza JM, Kahn MF, et al: Vasculitides associated
with malignancies: analysis of sixty patients. Arthritis Rheum 2007,
57:1473–1480.
doi:10.1186/1752-1947-6-261
Cite this article as: Wong et al.: Paraneoplastic leukocytoclastic vasculitis
as an initial presentation of malignant pleural mesothelioma: a case
report. Journal of Medical Case Reports 2012 6:261.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
